National Institute for Health and Clinical Excellence

[document type for example, IFP, QRG] on [topic] Document cover sheet

Date	Version	Editor	Action
Date	number		
140817	1	AM	Preconsultation edit

1

2

3	
4 5	NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
6	Guideline scope
7 8	Diverticular disease: diagnosis and management
9 10	The Department of Health in England has asked NICE to develop a clinical guideline on diverticular disease.
11 12	The guideline will be developed using the methods and processes outlined in <u>Developing NICE guidelines: the manual</u> .
13 14	This guideline will also be used to develop the NICE quality standard for diverticular disease.
15	1 Why the guideline is needed
16	Key facts and figures
 17 18 19 20 21 22 23 24 	Diverticular disease is a digestive condition characterised by small pouches (diverticula) that protrude from the walls of the large intestine. Diverticula can be present without any symptoms and in most people it remains undiagnosed. This is called diverticulosis., It may be revealed by investigations for other problems. When symptoms occur, this is known as diverticular disease. Symptoms include non-specific abdominal complaints, bloating, altered bowel habit and bleeding from the rectum. Acute diverticulitis occurs when a diverticulum becomes inflamed or infected. Symptoms can include constant
25 26	abdominal pain, alteration in bowel habit, fever or tachycardia, and large rectal bleeds.
27 28	Most people with diverticula (approximately 75%) will remain asymptomatic. Of the 25% of people with diverticula who develop symptomatic diverticular

29 disease, approximately 75% will have at least 1 episode of diverticulitis, and a

- 30 third of those with diverticulitis develop complications. These complications
- 31 include abscesses and perforation of the bowel.
- 32 Diverticular disease is rare in people younger than 40 years and it increases
- 33 with age. Approximately 50% of people have diverticula (symptomatic or
- 34 asymptomatic) by age 50, and approximately 70% of people have diverticula
- 35 by age 80.
- 36 From 2008 to 2010 there were 5,025 deaths in England recorded with an
- 37 underlying diagnosis of diverticular disease. There was a 1.3-fold difference in
- 38 mortality rates between the strategic health authority with the highest rate
- 39 compared with the one with the lowest, with rates being highest in the North
- 40 West of England.

41 **Current practice**

- 42 Asymptomatic diverticulosis that has been identified incidentally is not
- 43 evaluated further through diagnostic testing. The person is advised to
- 44 increase fibre intake and physical activity.
- 45 People who develop diverticular disease are prescribed analgesics such as
- 46 paracetamol, in addition to being given dietary advice. Those who have
- 47 significant blood loss may need to be admitted to hospital for a blood
- 48 transfusion.
- 49 People with mild, uncomplicated diverticulitis can usually have their condition
- 50 managed at home. People with suspected complications such as abcesses
- 51 and perforations need to be admitted to hospital.
- 52 In England there is geographic and demographic variation in access to
- 53 secondary care for the management of diverticular disease. This guideline
- aims to help reduce this variation and give more people access to the care
- 55 they need.

56 **Policy, legislation, regulation and commissioning**

57 There are currently no policy documents relating to diverticular disease.

58 **2** Who the guideline is for

- 59 People using services, their families and carers, and the public will be able to
- 60 use the guideline to find out more about what NICE recommends, and help
- 61 them make decisions.
- 62 This guideline is for:
- People using services, their families and carers, and the public.
- Healthcare professionals in primary care.
- Healthcare professionals in secondary care.
- 66 NICE guidelines cover health and care in England. Decisions on how they
- 67 apply in other UK countries are made by ministers in the Welsh Government,
- 68 <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>.

69 Equality considerations

- 70 NICE has carried out an equality impact assessment [add hyperlink in final
- 71 **version]** during scoping. The assessment:
- lists equality issues identified, and how they have been addressed
- explains why any groups are excluded from the scope.
- 74 The guideline will look at inequalities relating to people of Asian family origin.

75 **3** What the guideline will cover

76 **3.1** Who is the focus?

77 Groups that will be covered

- Adults 18 years and over with suspected or confirmed diverticular disease.
- 79 Specific consideration will be given to people of Asian family origin as they are
- 80 known to develop right-sided diverticula.

81 Groups that will not be covered

• Children and young people aged 17 years and younger.

83 **3.2 Settings**

- 84 The guideline will cover all settings where NHS care is provided or
- 85 commissioned.

86 **3.3** Activities, services or aspects of care

87 Key areas that will be covered

- 88 We will look at evidence in the areas below when developing the guideline,
- 89 but it may not be possible to make recommendations in all the areas.
- 90 1 Diverticulosis - Management of diverticulosis. including: 91 92 • Dietary advice (dietary fibre: soluble and insoluble) 93 Probiotics 94 Other conservative management (for example exercise). 2 Diverticular disease 95 96 Diagnosis of diverticular disease: 97 Signs and symptoms 98 Investigations (for example colonoscopy, sigmoidoscopy, CT 99 and MRI). 100 - Management of diverticular disease including: 101 • High fibre diet (soluble and insoluble fibre) 102 Bulk forming laxatives 103 • Fluids 104 Antibiotics 105 Analgesia (including paracetamol, non-steroidal anti-106 inflammatory drugs [NSAIDs] and opiates) 107 Antispasmodics 108 Aminosalicylates 109 Management of recurrent episodes of diverticular disease. 110 3 Acute diverticulitis - Diagnosis of acute diverticulitis: 111

112	 Investigations (for example full blood count, C-reactive protein, 		
113	CT and MRI).		
114	 Management of acute diverticulitis, for example: 		
115	 Bowel rest (clear fluids only) 		
116	IV fluids		
117	 Antibiotics (including choice of antibiotic and route of 		
118	administration)		
119	Analgesia		
120	 Referral for hospital admission 		
121	 Indications for surgery 		
122	 Choice of surgical intervention (for example elective or 		
123	emergency, open or laparoscopic resection, extent of colectomy,		
124	timing of anastomosis).		
125	 Management of complications (for example abcesses and bowel 		
126	perforation).		
127	 Management of recurrent episodes of acute diverticulitis. 		
128	4 Information and support needs (for people and their families).		
129	Note that guideline recommendations for medicines will normally fall within		
130	licensed indications; exceptionally, and only if clearly supported by evidence,		
131	use outside a licensed indication may be recommended. The guideline will		
132	assume that prescribers will use a medicine's summary of product		
133	characteristics to inform decisions made with individual patients.		
134	Areas that will not be covered		
135	1 Prevention.		
136	2 Management of bleeding.		
137	NICE guidance about the experience of people using NHS services		
138	NICE has produced the following guidance on the experience of people using		
139	the NHS. This guideline will not include additional recommendations on these		
140	topics unless there are specific issues related to diverticular disease:		
141	Medicines optimisation (2015) NICE guideline NG5.		

- 142 Patient experience in adult NHS services (2012) NICE guideline CG138.
- <u>Service user experience in adult mental health</u> (2011) NICE guideline
- 144 CG136.
- <u>Medicines adherence</u> (2009) NICE guideline CG76.

146**3.4Economic aspects**

147 We will take economic aspects into account when making recommendations.

- 148 We will develop an economic plan that states for each review question (or key
- 149 area in the scope) whether economic considerations are relevant, and if so
- 150 whether this is an area that should be prioritised for economic modelling and
- analysis. We will review the economic evidence and carry out economic
- analyses, using an NHS and personal social services (PSS perspective, as
- 153 appropriate.

154 **3.5** Key issues and questions

While writing this scope, we have identified the following key issues, and draftreview questions, related to them:

- 157 1 Diverticulosis
- 158 1.1 What is the most clinically and cost effective conservative
- 159 management for diverticulosis, for example:
- Dietary advice (dietary fibre: soluble and insoluble fibre)
- 161 Probiotics
- Other conservative management (for example exercise)?
- 163 2 Diverticular disease
- 164 Diagnosis of diverticular disease:
- 2.1 What signs and symptoms indicate diverticular disease as a possiblediagnosis?
- 167 2.2 In which people with suspected diverticular disease should168 investigations be performed?
- 169 2.3 What is the most accurate and cost effective test (for example
- 170 colonoscopy, sigmoidoscopy, CT and MRI) in the diagnosis of171 diverticular disease?

172		 Management of diverticular disease:
173		2.4 What are the most clinically and cost effective treatments for
174		confirmed uncomplicated diverticular disease (that is, with mild
175		abdominal pain or tenderness and no systemic symptoms)? For
176		example:
177		 High fibre diet (soluble and insoluble fibre)
178		Bulk forming laxatives
179		• Fluids
180		Antibiotics
181		 Analgesia (including paracetamol, non-steroidal anti-inflammatory
182		drugs [NSAIDs] and opiates)
183		Antispasmodics
184		Aminosalicylates.
185		2.5 What is the most clinically and cost effective management strategy
186		for people with recurrent episodes of diverticular disease?
187	3	Acute diverticulitis
188		 Diagnosis of acute diverticulitis:
189		3.1 Which investigations are clinically and cost effective (for example
190		full blood count, CRP, CT and MRI) in the diagnosis and
191		assessment of acute diverticulitis?
192		 Management of acute diverticulitis:
193		3.2 What are the most clinically and cost effective non-surgical
194		treatments for acute diverticulitis, including recurrent episodes? For
195		example:
196		 Bowel rest (clear fluids only)
197		IV fluids
198		 Antibiotics (including antibiotic or no antibiotic, choice of antibiotic
199		and route of administration)
200		Analgesia.
201		3.3 When should people with acute diverticulitis be referred for hospital
202		admission?
203		3.4 What are the indications for surgery in people with acute
204		diverticulitis?

205		3.5 What are the clinically and cost effective surgical approaches to				
206		management of acute diverticulitis, including:				
207		 Timing of surgery (elective or emergency) 				
208	 Open or laparoscopic resection 					
209		Extent of colectomy				
210		 Timing of anastomosis (primary or secondary)? 				
211		3.6 What is the clinical and cost effectiveness of percutaneous drainage				
212		versus resectional surgery for the management of abscesses?				
213		3.7 What is the clinical and cost effectiveness of laparoscopic lavage				
214		versus resectional surgery for the management of bowel				
215		perforations?				
216		3.8 What is the most clinically and cost effective management strategy				
217		for people with recurrent episodes of acute diverticulitis?				
218	4	Information for patients				
219		4.1 What information and support do people with diverticular disease				
220		need?				
221	The	key questions may be used to develop more detailed review questions,				
222	whic	ch guide the systematic review of the literature.				
223	3.6	Main outcomes				
224	The	e main outcomes that will be considered when searching for and assessing				
225	the e	e evidence are:				
226	1	Quality of life.				
227	2	Mortality.				
228	3	Diagnostic test accuracy.				
229	4	Progression of disease.				
230	5	Side effects of:				
231		 antibiotics, for example nausea and vomiting 				
232		 analgesics, for example constipation 				
233		 surgery, for example morbidity and mortality. 				
234	6	Symptom control, for example pain relief.				
235	7	Recurrence rates of acute diverticulitis.				
236	8	Hospitalisation.				

- 237 9 Need for surgery.
- 238 10 Complications, for example:
- 239 infections
- 240 abscesses
- 241 perforation.

242 **4 NICE quality standards and NICE Pathways**

243 4.1 NICE quality standards

244 NICE quality standards that may use this guideline as an evidence


source when they are being developed

- [Title of quality standard] NICE quality standard. Publication expected
- 247 [Month Year] [or] Publication date to be confirmed
- [Use 'Bullet left 1 last' style for final point.]

249 **4.2 NICE Pathways**

- 250 <u>NICE Pathways</u> bring together everything we have said on a topic in an
- 251 interactive flowchart. When this guideline is published, the recommendations
- 252 will be included in the NICE Pathway on diverticular disease (in development).
- 253 It will be accessible from the NICE Pathway on <u>gastrointestinal conditions</u>.
- 254 Other relevant guidance will also be added, including:
- Quantitative faecal immunochemical tests to guide referral for colorectal
 cancer in primary care (2017) NICE diagnostics guidance 30
- <u>Computed tomographic colonography (virtual colonoscopy)</u> (2005) NICE
- 258 interventional procedure guidance 129
- 259
- 260 An outline based on this scope is included below. It will be adapted and more
- 261 detail added as the recommendations are written during guideline
- development. Links will be added to relevant NICE Pathways, for example
- 263 <u>colorectal cancer</u>, <u>Crohn's disease</u>, <u>irritable bowel syndrome in adults</u>,
- 264 <u>suspected cancer recognition and referral</u>, and <u>ulcerative colitis</u>.





266

5 Further information

This is the draft scope for consultation with registered stakeholders. The consultation dates are 22 August to 20 September 2017.

The guideline is expected to be published in October 2019.

You can follow progress of the guideline.

[After consultation, delete the first paragraph above and replace it with 'This is the final scope, incorporating comments from registered stakeholders during

consultation'.]

Our website has information about how <u>NICE guidelines</u> are developed.

268